

Xinna Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9152995/publications.pdf>

Version: 2024-02-01

20
papers

1,685
citations

516561

16
h-index

713332

21
g-index

22
all docs

22
docs citations

22
times ranked

3503
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>CCAT2</i> , a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. <i>Genome Research</i> , 2013, 23, 1446-1461.	2.4	526
2	TP53 loss creates therapeutic vulnerability in colorectal cancer. <i>Nature</i> , 2015, 520, 697-701.	13.7	192
3	Oncogenic Wip1 Phosphatase Is Inhibited by miR-16 in the DNA Damage Signaling Pathway. <i>Cancer Research</i> , 2010, 70, 7176-7186.	0.4	159
4	Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. <i>EBioMedicine</i> , 2018, 38, 100-112.	2.7	159
5	Amplification of USP13 drives ovarian cancer metabolism. <i>Nature Communications</i> , 2016, 7, 13525.	5.8	99
6	The RNA-Binding Protein DDX1 Promotes Primary MicroRNA Maturation and Inhibits Ovarian Tumor Progression. <i>Cell Reports</i> , 2014, 8, 1447-1460.	2.9	86
7	Targeting tumor suppressor genes for cancer therapy. <i>BioEssays</i> , 2015, 37, 1277-1286.	1.2	65
8	MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	63
9	miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 25930-25948.	0.8	49
10	An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity. <i>Nature Biomedical Engineering</i> , 2021, 5, 1320-1335.	11.6	49
11	Noncoding RNAs in DNA Repair and Genome Integrity. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 655-677.	2.5	44
12	Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer. <i>Nature Communications</i> , 2018, 9, 4718.	5.8	44
13	MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. <i>Modern Pathology</i> , 2016, 29, 330-346.	2.9	33
14	ST2 as checkpoint target for colorectal cancer immunotherapy. <i>JCI Insight</i> , 2020, 5, .	2.3	29
15	Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II. <i>Nature Communications</i> , 2018, 9, 4394.	5.8	27
16	Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. <i>Human Pathology</i> , 2018, 77, 121-129.	1.1	20
17	Targeted immunotherapy for HER2-low breast cancer with 17p loss. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	14
18	PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1882.	1.8	13

#	ARTICLE	IF	CITATIONS
19	Metabolic interventions: A new insight into the cancer immunotherapy. Archives of Biochemistry and Biophysics, 2021, 697, 108659.	1.4	8
20	Profiling Long Non-coding RNA expression Using Custom-Designed Microarray. Methods in Molecular Biology, 2021, 2372, 43-51.	0.4	0